CureVac Is Incredibly Overvalued And Perfectly Captures The Insanity Of The U.S. Stock Market In 2020

I describe that value as astonishing because the company recorded revenues of $3.1 million, down slightly year-on-year, in its most recently reported quarter, ending March 31st.